Oncoclínicas do Brasil Serviços Médicos (ONCO3) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
14 Jul, 2026Executive summary
Q2 2025 was marked by commercial and operational transition, with revenues flat sequentially as contracts with high-delinquency or low-margin payors were phased out, while growth continued with other clients.
Adjusted EBITDA rebounded 38.3% quarter-over-quarter, with margin expansion despite lower net revenues.
Net loss ranged from R$136.8 million to R$142.3 million in Q2 2025, reversing net income from Q2 2024, mainly due to lower operating leverage and higher financial expenses.
Cash flow consumption increased, driven by client delinquency, higher interest expenses, and growth capex.
Strategic initiatives included discontinuing low-margin contracts, headcount optimization (~400 reduction since Q3 2024), vendor contract reviews, capex reprioritization, and a strategic review of non-core assets.
Financial highlights
Gross revenue in Q2 2025 was approximately R$1,657.6 million, stable sequentially but down 3.8% year-over-year; net revenue fell 6.6% year-over-year to R$1,464.4 million.
Adjusted EBITDA reached R$185.1 million (12.6% margin), up 38.3% sequentially but down 41.7% year-over-year.
Net loss for Q2 2025 was R$142.3 million, with negative operational cash flow of R$196.1 million, mainly from late payments by discontinued clients.
Cash gross margin improved 250 bps quarter-over-quarter to 30.3%, but declined year-over-year.
Net financial result was negative R$175.1 million, a slight improvement from Q2 2024.
Outlook and guidance
Sequential revenue deceleration expected in Q3 2025 due to the end of services for Unimed FERJ and Unifers starting August.
Medium-term growth anticipated from new contracts, client base recycling, and new cancer centers and medical facilities.
Capex plan and non-core hospital operations under strategic review for reprioritization.
Saudi Arabia JV projected to reach US$550 million gross revenue and US$150 million EBITDA by year five, but remains pre-operational.
Latest events from Oncoclínicas do Brasil Serviços Médicos
- Revenue up 13.5% in 2024, but net loss of R$717M due to impairment and higher costs.ONCO3
Q4 202414 Jul 2026 - Revenue and cash flow surged, but net income fell on higher taxes and restructuring costs.ONCO3
Q3 202414 Jul 2026 - Gross revenue up 16%, leverage down to 2.5x, and first international JV announced.ONCO3
Q2 202414 Jul 2026 - Revenue growth slowed and margins compressed, but cash flow and working capital improved.ONCO3
Q1 202514 Jul 2026 - Net loss hit R$3.67 billion amid defaults, liquidity stress, and major restructuring actions.ONCO3
Q4 202514 Jul 2026 - Revenue and profitability declined sharply amid operational and financial pressures.ONCO3
Q1 202614 Jul 2026 - Adjusted EBITDA rose 30.4% QoQ as operational efficiency offset revenue declines.ONCO3
Q3 202514 Jul 2026